grant
Cancer Microenvironment Research Program
Organization UNIVERSITY OF ROCHESTERLocation ROCHESTER, UNITED STATESPosted 15 Mar 2025Deadline 28 Feb 2030
NIHUS FederalResearch GrantFY2026AccelerationAchievementAchievement AttainmentAcuteAddressAgingAnimalsAntibodiesAreaAttentionAutoregulationBasic Cancer ResearchBasic ResearchBasic ScienceBiological MarkersBiology of AgingBody TissuesBone MarrowBone Marrow Reticuloendothelial SystemCancer ControlCancer Control Research ProgramCancer Control ScienceCancer InductionCancer ModelCancer SurvivorCancer TreatmentCancerModelCancersCatchment AreaCell BodyCell CommunicationCell Communication and SignalingCell InteractionCell SignalingCell-to-Cell InteractionCellsCellular immunotherapyClinicClinicalClinical TrialsCollaborationsCommunitiesCommunity OutreachComplementComplement ProteinsDNA mutationDevelopmentDiseaseDisorderDoctor of PhilosophyDrug TargetingDysfunctionEarly-Stage Clinical TrialsElderlyEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFosteringFunctional disorderFundingFutureGI cancersGI malignanciesGI tract cancersGastrointestinal CancerGastrointestinal Tract CancerGeneralized GrowthGeneticGenetic ChangeGenetic ModelsGenetic defectGenetic mutationGoalsGrantGrowthHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoieticHematopoietic CancerHeterogeneityHodgkin DiseaseHodgkin DisorderHodgkin lymphomaHodgkin'sHodgkin's LymphomaHodgkin's diseaseHodgkins lymphomaHomeostasisImageImmuneImmune mediated therapyImmunesImmunityImmunologically Directed TherapyImmunologyImmunotherapyIncidenceInjuryInnate ImmunityInstitutionIntermediary MetabolismIntracellular Communication and SignalingInvestigatorsInvestmentsLeadLeadershipMalignant Gastrointestinal NeoplasmMalignant Hematologic NeoplasmMalignant LymphogranulomaMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant Pancreatic NeoplasmMalignant TumorMalignant lymphoid neoplasmMalignant neoplasm of gastrointestinal tractMalignant neoplasm of pancreasMediatorMentorsMentorshipMetabolicMetabolic ProcessesMetabolismMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMissionMorbidityMutationMyeloid DiseaseMyeloid MalignancyMyeloid NeoplasmMyeloid TumorMyeloid-derived suppressor cellsMyeloproliferative DisordersMyeloproliferative TumorsMyeloproliferative diseaseNanotechnologyNative ImmunityNatural ImmunityNeoplasm MetastasisNew YorkNon-Specific ImmunityNonspecific ImmunityNormal TissueNormal tissue morphologyOpticsOrganOutcomePancreas CancerPancreas Ductal AdenocarcinomaPancreatic CancerPancreatic Ductal AdenocarcinomaPaperPatientsPb elementPeer ReviewPh.D.PhDPhase 1 Clinical TrialsPhase I Clinical TrialsPhysiciansPhysiological HomeostasisPhysiopathologyPopulationPostdocPostdoctoral FellowPre-Clinical ModelPreclinical ModelsPublishingRadiationRadiation BiologyRadiation therapyRadiobiologyRadiotherapeuticsRadiotherapyResearchResearch ActivityResearch AssociateResearch PersonnelResearch SpecimenResearchersResource SharingRisk ReductionRoleScientistSecondary NeoplasmSecondary TumorSeminalSignal InductionSignal TransductionSignal Transduction SystemsSignalingSpecimenStrategic PlanningTestingTherapeuticTissue GrowthTissuesToxic effectToxicitiesTrainingTraining ProgramsTranslatingTranslational ResearchTranslational Research Working GroupTranslational ScienceTranslationsTreatment EfficacyTumor BurdenTumor ImmunityTumor LoadUniversitiesUpdateWorkadaptive immunityadvanced ageanti-canceranti-cancer therapyanti-tumor immunityantitumor immunitybio-markersbiologic markerbiological signal transductionbiomarkercancer cell metabolismcancer immunitycancer immunologycancer initiationcancer metabolismcancer metastasiscancer microenvironmentcancer preventioncancer progenitorcancer progenitor cellscancer stem cellcancer stem like cellcancer therapycancer-directed therapycarcinogenesiscareercell-based immunotherapycheck point inhibitioncheckpoint inhibitionclinical translationclinically translatablecollaboration with communitiescommunity collaborationcommunity engagementcommunity-based collaborationcomplementationcompound repositioningcompound repurposingdevelopmentaldrug repositioningdrug repurposingearly-career facultyengagement with communitiesepigeneticallyfitnessflow cytophotometryfull professorgastrointestinal malignanciesgenome mutationgeriatricheavy metal Pbheavy metal leadhemopoieticimagingimmune cell therapyimmune check point inhibitionimmune checkpoint inhibitionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunosuppressive myeloid cellsimprovedin vivo Modelinjuriesinjury to tissueinnovateinnovationinnovativeinterestintervention efficacylymphoid cancerslymphoid malignancymalignancymalignant progenitormalignant stem cellmembermulti-modalitymultidisciplinarymultimodalitymyeloid suppressor cellsmyeloid-derived suppressive cellsmyeloproliferative neoplasmnano technano technologynano-technologicalnanotechnanotechnologicalneoplasm immunologyneoplasm/cancernew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew technologynew therapeutic targetnew therapeutic uses for existing drugsnew therapeuticsnew therapynew therapy targetnew use of drugnew uses for an approved drugnew uses for existing drugsnext generationnext generation therapeuticsnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel technologiesnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetoncogenic progenitoroncogenic stem cellsontogenyopticalpancreatic malignancypathophysiologypharmacological repurposingphase I protocolpost-docpost-doctoralpost-doctoral traineepre-clinicalpre-docpre-doctoralpreclinicalprogenitor biologyprogenitor cell biologyprogenitor like cancer cellprogramsradiation treatmentrecruitreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskrepositioning approved drugsrepositioning existing drugsrepurpose approved drugsrepurpose approved medicationrepurpose approved therapeuticrepurpose existing drugsrepurpose existing medicationrepurpose existing medicinerepurpose existing therapeuticsrepurpose existing therapiesrepurpose medicinerepurposing a drugrepurposing agentrepurposing candidatesrepurposing established drugsrepurposing established medicationrepurposing existing pharmacological agentsrepurposing medicationrepurposing of already existing drugsrepurposing pharmaceuticalsresearch associatesresistance to therapyresistant to therapyresponseresponse to therapyresponse to treatmentrisk-reducingruralitysenior citizensenior facultysocial rolestem and progenitor biologystem cell biologystem like cancer cellsuppressive myeloid cellstherapeutic efficacytherapeutic repositioningtherapeutic repurposingtherapeutic resistancetherapeutic responsetherapy efficacytherapy resistanttherapy responsetissue injurytissue repairtranslationtranslation researchtranslational investigationtreatment resistancetreatment responsetreatment responsivenesstreatment with radiationtumortumor cell metabolismtumor cell metastasistumor immunologytumor metabolismtumor microenvironment
Description preview
CANCER MICROENVIRONMENT RESEARCH PROGRAM: PROJECT SUMMARY/ABSTRACT
The goal of the Cancer Microenvironment (CM) research program at the Wilmot Cancer Institute (Wilmot) is to understand how tissue microenvironments control cancer initiation, progression, and treatment. In addition to seminal contributions toward the definition of key cell…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click